Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2866853 | 0.89 | MAPT (0.36) | EPHX2CA2MAPTKMT2AMEN1 | |
| SCHEMBL2859668 | 0.87 | GSK3B (0.37) | EPHX2CA2 | |
| SCHEMBL2861331 | 0.87 | MAPT (0.43) | EPHX2CSNK1DCA2MAPTPPARA | |
| SCHEMBL2859926 | 0.87 | CA2 (0.45) | CA2 | |
| SCHEMBL2866713 | 0.86 | EPHX2 (0.34) | EPHX2CSNK1DCA2MAPTKMT2A | |
| SCHEMBL544323 | 0.85 | EPHX2 (0.44) | EPHX2CSNK1DCA2MAPTKMT2A | |
| SCHEMBL2855117 | 0.85 | CA2 (0.40) | EPHX2CSNK1DCA2MAPTKMT2A | |
| SCHEMBL2861474 | 0.84 | DYRK1A (0.35) | EPHX2CSNK1DCA2MAPTKMT2A | |
| SCHEMBL2862154 | 0.84 | EPHX2 (0.34) | EPHX2CA2MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL544321 | 0.83 | MAPT (0.38) | EPHX2CSNK1DCA2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370260-B1 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-11-24 | — | — | EP | claimed |
| US-7709510-B2 | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | claimed |
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-13 | — | — | US | claimed |
| EP-1370260-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-12-17 | — | — | EP | claimed |
| WO-2002066035-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-29 | — | — | WO | claimed |
| US-8110686-B2 | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKI KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110686-B2 | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKI KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20110028514-A1 | Azoles as Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110028514-A1 | Azoles as Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-02-03 | — | — | US | disclosed |
| US-7709510-B2 | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | disclosed |
| US-7709510-B2 | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028514-A1 | Azoles as Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | ME3, ME1, MLYCD | EPHX2 1509/4885CSNK1D 1308/4885CA2 430/4885 |
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | ME1, ME3, ME2 | EPHX2 1552/4885CSNK1D 1024/4885CA2 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.